newsfilter
← Latest News
Business Wire·

Cortexyme Announces Clinical Hold on Atuzaginstat's Investigational New Drug Application

Cortexyme, Inc. (NASDAQ:CRTX), a clinical-stage biopharmaceutical company focused on Alzheimer's and other degenerative diseases, today announced that the company received a letter from the U.S. Food and Drug Administration (FDA) on January 25, 2022 pla